Sutro’s Commitment to Patients

 

The fight against cancer is all too familiar. The potential effectiveness and precision of Sutro’s clinical candidates may change the way patients battle cancer. The advancements Sutro has made with our CellFree technology and the ability to manufacture with rigorous GMP standards, is advancing treatment options for patients.

Learn more about Sutro’s Whitepaper, “STRO-002 from Sutro Biopharma offers hope to patients with rare, otherwise fatal pediatric tumors. Sutro Biopharma’s STRO-002 puts young leukemia patients into remission“

Clinical Trials

Sutro is currently advancing two wholly owned clinical-stage programs that are designed to provide patient benefits across multiple areas of unmet need.

For More Info

Commitment To Patients

Sutro’s technology enables us to design and test complex molecules as potential next generation cancer treatments in a rapid cycle of weeks rather than months. 

For More Info

Compassionate Use Access

Sutro will consider providing individual patients compassionate use access to an investigational medicine outside of a clinical trial only when all criterias are met.

For More Info

Proud member of OCRA’s Ovarian Cancer Industry Council

Thank You 

Our Sutro team would like to express our heart-felt thanks to the patients, their families and health care providers for participating in our clinical studies.